Investors Purchase Large Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) was the target of unusually large options trading on Monday. Investors purchased 7,866 call options on the stock. This is an increase of 1,998% compared to the typical volume of 375 call options.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday. Lake Street Capital lifted their price objective on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Checkpoint Therapeutics during the third quarter valued at about $30,000. XTX Topco Ltd purchased a new stake in Checkpoint Therapeutics in the second quarter worth about $34,000. Gladstone Institutional Advisory LLC lifted its holdings in shares of Checkpoint Therapeutics by 141.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company's stock valued at $78,000 after purchasing an additional 20,500 shares during the last quarter. Magnus Financial Group LLC lifted its holdings in shares of Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company's stock valued at $78,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Choreo LLC lifted its holdings in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company's stock valued at $133,000 after purchasing an additional 7,080 shares during the last quarter. Institutional investors own 22.00% of the company's stock.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT traded down $0.28 during midday trading on Monday, reaching $3.39. The company's stock had a trading volume of 16,494,230 shares, compared to its average volume of 624,046. Checkpoint Therapeutics has a 12-month low of $1.36 and a 12-month high of $4.50. The firm has a 50 day moving average price of $3.50 and a 200-day moving average price of $2.67. The stock has a market capitalization of $165.53 million, a P/E ratio of -1.84 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts predict that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.